Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 4/20 | 0.48 |
| ▸ | PLG | P00747 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21621476 | 0.87 | MAPT (0.52) | PPARGACE2ELANEPLGL3MBTL1 | |
| SCHEMBL7948778 | 0.87 | PPARG (0.60) | ADORA3PPARGACE2ELANEPLG | |
| Benzquercin SCHEMBL1057326 | 0.82 | PPARG (0.66) | ADORA3PPARGACE2ELANEPLG | |
| SCHEMBL31236659 | 0.81 | ADORA3 (0.69) | ADORA3PPARGACE2ELANEPLG | |
| SCHEMBL20630735 | 0.81 | ADORA3 (0.69) | ADORA3PPARGACE2ELANEPLG | |
| SCHEMBL7545480 | 0.81 | PPARG (0.70) | ADORA3PPARGACE2ELANEPLG | |
| SCHEMBL16160543 | 0.80 | PPARG (0.58) | ADORA3PPARGACE2ELANEPLG | |
| SCHEMBL28573367 | 0.79 | PPARG (0.53) | ADORA3PPARGACE2ELANEPLG | |
| SCHEMBL1144343 | 0.79 | ACE2 (0.62) | ADORA3PPARGACE2PLG | |
| SCHEMBL20630746 | 0.79 | ACE2 (0.55) | ADORA3PPARGACE2ELANEPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139447-A1 | Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-13 | — | — | US | disclosed |
| WO-2020012003-A1 | LIPOPHENOLIC FLAVONOID DERIVATIVES USEFUL TO REDUCE CARBONYL AND OXIDATIVE STRESSES (COS) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139447-A1 | Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) | LPO, NQO1, CAT | ADORA3 4848/4885PPARG 336/4885ACE2 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.